Skip to content

Released Nov 15, 2021, before the open

10-Q filed Nov 15, 2021, 46 days after period end · 0001558370-21-015862

Q3 2021 · 10-Q
Revenue$12.05M+11.7% vs Q3 2020+87.6% vs Q2 2021
Net Income-$4.20MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.09N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$1,885,000N/M
Operating Cash Flowderived-$1,880,000N/M
Free Cash Flowderived-$2,224,000N/M
Margins · derived
Operating margin-15.6%+8.3 pt vs Q3 2020
Net margin-34.8%+6.3 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$12.05M$10.79M$14.25M$663.00K
Net Income-$4.20M-$4.44M-$3.56M-$5.32M
EPS Diluted-$0.09-$0.14-$0.24-$0.40

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR